<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>6
<FILENAME>form8kitem101ex992may-15.txt
<DESCRIPTION>EXHIBIT 99.2 PRESS RELEASE
<TEXT>




                                  EXHIBIT 99.2




<PAGE>


8229 Boone Boulevard, Suite 802                             COMPANY CONTACT:
Vienna, VA  22182.  USA                                     Gavin de Windt
Telephone (703) 506-9460                                    CEL-SCI Corporation
www.cel-sci.com                                             (703) 506-9460


                CEL-SCI PRICES UP TO $16 MILLION PUBLIC OFFERING
                          OF COMMON STOCK AND WARRANTS


Vienna, VA, May 22, 2015 - CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the
"Company")  today announced that it has priced a best efforts offering of common
stock and  warrants  at a  combined  price of $0.79 per unit of  securities  for
aggregate  gross  proceeds of up to $16 million,  prior to  deducting  placement
agent  commissions  and offering  expenses.  Each unit  consists of one share of
common stock and one warrant to purchase one share of common  stock.  The common
stock and warrants  will  separate  immediately.  The  warrants are  immediately
exercisable, expire in five-years and have an exercise price of $0.79 per share.
This  offering  is expected  to close on or about May 28,  2015,  subject to the
satisfaction of customary closing conditions.

CEL-SCI  intends  to use the net  proceeds  of the  offering  for its  Phase III
clinical trial, an ongoing Phase I study in HIV/HPV  co-infected  patients other
research and  development,  repayment of a $1.1 million note, held in a trust of
which the Company's  chief  executive  officer is the trustee and a beneficiary,
due  in  July  2015  and  general  and  administrative  expenses.  Dawson  James
Securities, Inc. is acting as the sole placement agent for the proposed offering
on a best efforts basis.

A shelf registration  statement on Form S-3 declared effective by the Securities
and  Exchange  Commission  ("SEC") on July 8,  2014,  a  preliminary  prospectus
supplement and accompanying  prospectus  related to the offering have been filed
with   the  SEC  and  are   available   on  the   SEC's   website   located   at
http://www.sec.gov.  The  offering  may be made only by means of the  prospectus
supplement  and  accompanying  prospectus,  copies of which may be obtained from
Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal
Highway, 5th Floor, Boca Raton, FL 33432, mmaclaren@dawsonjames.com or toll free
at 866.928.0928.

This press release shall not constitute an offer to sell or the  solicitation of
an offer to buy any securities,  nor shall there be any sale of these securities
in any state or other  jurisdiction in which such offer,  solicitation,  or sale
would be unlawful prior to  registration or  qualification  under the securities
laws of such state or other jurisdiction.

                                       1
<PAGE>

Forward-Looking Statement

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans"  and  "expects"  and
similar  expressions  are  intended  to  identify  forward-looking   statements.
Forward-looking statements include, without limitation, the Company's ability to
complete  the  proposed  offering.  Such  statements  are  subject  to risks and
uncertainties  which could cause actual results to differ  materially from those
projected.  CEL-SCI  undertakes no obligation to publicly  release the result of
any revision to these forward-looking statements that may be made to reflect the
events or  circumstances  after the date hereof or to reflect the  occurrence of
unanticipated events.
</TEXT>
</DOCUMENT>
